- Conditions
- Fibromyalgia
- Interventions
- [S,S]-Reboxetine
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 390 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 101
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 87 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 193–216
of 5,300
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Metastatic Renal Cell Carcinoma, Metastatic Melanoma
- Interventions
- Aldesleukin
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Aurora, Colorado • Louisville, Kentucky + 1 more
- Conditions
- Crohn Disease
- Interventions
- Placebo for Ustekinumab, Placebo for Adalimumab, Ustekinumab (6 mg/kg), Ustekinumab (90 mg), Adalimumab (40 mg)
- Biological
- Lead sponsor
- Janssen Scientific Affairs, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 386 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 67
- States / cities
- Mobile, Alabama • San Diego, California • Colorado Springs, Colorado + 60 more
- Conditions
- Anaplastic Astrocytoma, Anaplastic Astrocytoma, Not Otherwise Specified, Anaplastic Ganglioglioma, Anaplastic Pleomorphic Xanthoastrocytoma, Glioblastoma, Malignant Glioma, WHO Grade 3 Glioma, WHO Grade 4 Glioma
- Interventions
- Biospecimen Collection, Dabrafenib Mesylate, Lumbar Puncture, Magnetic Resonance Imaging, Radiation Therapy, Trametinib Dimethyl Sulfoxide
- Procedure · Drug · Radiation
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 3 Years to 25 Years
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 130
- States / cities
- Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 106 more
- Conditions
- Urinary Bladder, Overactive
- Interventions
- Mirabegron, Placebo
- Drug
- Lead sponsor
- Astellas Pharma Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,030 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 82
- States / cities
- Homewood, Alabama • Huntsville, Alabama • Mobile, Alabama + 75 more
- Conditions
- Coronary Artery Disease
- Interventions
- Apadenoson
- Drug
- Lead sponsor
- Forest Laboratories
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,500 participants
- Timeline
- 2006
- U.S. locations
- 42
- States / cities
- Huntsville, Alabama • Santa Rosa, California • Bridgeport, Connecticut + 38 more
- Conditions
- COPD, COPD Exacerbation, Lung Diseases, Respiratory Disorders, Pulmonary Disease, Chronic Obstructive Lung Diseases, Chronic Obstructive Airway Disease
- Interventions
- Roflumilast, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 2,354 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 217
- States / cities
- Anniston, Alabama • Athens, Alabama • Florence, Alabama + 175 more
- Conditions
- Corneal Edema After Cataract Surgery
- Interventions
- Ripasudil, Placebo
- Drug
- Lead sponsor
- Kowa Research Institute, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 330 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 44
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Hemet, California + 37 more
- Conditions
- Ovarian Neoplasm
- Interventions
- CT-2103 (poly(L)glutamate-paclitaxel), carboplatin
- Drug
- Lead sponsor
- CTI BioPharma
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 82 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2006
- U.S. locations
- 17
- States / cities
- Greenbrae, California • Stockton, California • South Miami, Florida + 12 more
- Conditions
- Eosinophilic Asthma
- Interventions
- KT-621, Placebo
- Drug · Other
- Lead sponsor
- Kymera Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 264 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 34
- States / cities
- Lancaster, California • Long Beach, California • Northridge, California + 28 more
- Conditions
- Seasonal Allergic Rhinitis
- Interventions
- STAHIST, Placebo
- Drug
- Lead sponsor
- Magna Pharmaceuticals, Inc.
- Industry
- Eligibility
- 12 Years to 60 Years
- Enrollment
- 290 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011
- U.S. locations
- 8
- States / cities
- Stockbridge, Georgia • South Bend, Indiana • Louisville, Kentucky + 5 more
- Conditions
- Lung Cancer
- Interventions
- cisplatin, etoposide, radiation therapy
- Drug · Radiation
- Lead sponsor
- Radiation Therapy Oncology Group
- Network
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2010
- U.S. locations
- 242
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 189 more
- Conditions
- Constipation
- Interventions
- Lubiprostone
- Drug
- Lead sponsor
- University of Louisville
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 1
- States / cities
- Louisville, Kentucky
- Conditions
- End Stage Renal Disease (ESRD)
- Interventions
- soluble ferric pyrophosphate (SFP), placebo
- Drug · Other
- Lead sponsor
- Charles Drew University of Medicine and Science
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 2
- States / cities
- Los Angeles, California • Louisville, Kentucky
- Conditions
- Atherosclerotic Cardiovascular Disease
- Interventions
- Alirocumab, Placebo, LMT
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 18,924 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 273
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 218 more
- Conditions
- Fibrosing Colonopathy
- Interventions
- ULTRESA, PANCREAZE, CREON, ZENPEP, other non-sponsor pancreatic enzyme replacement therapy, PERTZYE, No pancreatic enzyme replacement therapy
- Biological · Other
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 0 Months to 99 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2020
- U.S. locations
- 123
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 102 more
- Conditions
- Pharmacokinetics
- Interventions
- esomeprazole
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- Up to 17 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 11
- States / cities
- Little Rock, Arkansas • Hartford, Connecticut • Park Ridge, Illinois + 8 more
- Conditions
- Scoliosis
- Interventions
- Surgical intervention, Non-operative intervention
- Procedure · Other
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 286 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2017
- U.S. locations
- 7
- States / cities
- Chicago, Illinois • Louisville, Kentucky • Baltimore, Maryland + 3 more
- Conditions
- Advanced Solid Tumors
- Interventions
- IPH5401 and Durvalumab
- Biological
- Lead sponsor
- Innate Pharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 73 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 5
- States / cities
- Louisville, Kentucky • Saint Louis Park, Minnesota • New York, New York + 2 more
- Conditions
- Breast Cancer
- Interventions
- Doxorubicin, Cyclophosphamide, Ixabepilone (Ixempra), Paclitaxel (Taxol)
- Drug
- Lead sponsor
- SCRI Development Innovations, LLC
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 614 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2016
- U.S. locations
- 69
- States / cities
- Anniston, Alabama • Huntsville, Alabama • Mobile, Alabama + 61 more
- Conditions
- Oral Mucositis
- Interventions
- AG013, Placebo
- Biological · Other
- Lead sponsor
- Oragenics, Inc.
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 27
- States / cities
- Farmington, Connecticut • Newark, Delaware • Orlando, Florida + 24 more
- Conditions
- Adult Cystic Nephroma, Anaplastic Kidney Wilms Tumor, Angiolipoma, Cellular Congenital Mesoblastic Nephroma, Classic Congenital Mesoblastic Nephroma, Clear Cell Sarcoma of the Kidney, Congenital Mesoblastic Nephroma, Cystic Partially Differentiated Kidney Nephroblastoma, Diffuse Hyperplastic Perilobar Nephroblastomatosis, Extrarenal Rhabdoid Tumor, Kidney Medullary Carcinoma, Kidney Neoplasm, Kidney Oncocytoma, Kidney Wilms Tumor, Metanephric Adenofibroma, Metanephric Adenoma, Metanephric Stromal Tumor, Metanephric Tumor, Mixed Congenital Mesoblastic Nephroma, Ossifying Renal Tumor of Infancy, Papillary Renal Cell Carcinoma, Renal Cell Carcinoma, Renal Cell Carcinoma Associated With Xp11.2 Translocations/TFE3 Gene Fusions, Rhabdoid Tumor of the Kidney, Wilms Tumor
- Interventions
- Cytology Specimen Collection Procedure, Laboratory Biomarker Analysis
- Other
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 29 Years
- Enrollment
- 8,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2026
- U.S. locations
- 214
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 153 more
- Conditions
- Breast Carcinoma, Fallopian Tube Carcinoma, Ovarian Neoplasm, Primary Peritoneal Carcinoma
- Interventions
- Evaluation of Cancer Risk Factors, Quality-of-Life Assessment, Questionnaire Administration, Study of High Risk Factors
- Procedure · Other
- Lead sponsor
- Gynecologic Oncology Group
- Network
- Eligibility
- 30 Years and older · Female only
- Enrollment
- 1,916 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2020
- U.S. locations
- 141
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 106 more
- Conditions
- Dermatitis, Dermatitis, Atopic, Eczema, Skin Diseases, Skin Diseases, Genetic, Genetic Diseases, Inborn, Skin Diseases, Eczematous, Hypersensitivity, Hypersensitivity, Immediate, Immune System Diseases
- Interventions
- PF-04965842 100 mg, PF-04965842 200 mg, Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 1,235 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 52
- States / cities
- Birmingham, Alabama • Fountain Valley, California • Fremont, California + 44 more